Evidence map›Paper›PMID 42169660›Full record

ReviewMolecular medicine reports2026

Targeting lipophagy in atherosclerosis: Molecular mechanisms, pathogenesis and therapeutic interventions (Review).

Songhua Nan, Chaojie Peng, Xue Meng, Jingnan Jia, Fangfang Zhao, Yinglin Cui

Abstract readReview
In one paragraph

Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Songhua NanDepartment of Rehabilitation Medicine, The Second Affiliated Hospital of Henan University of Chinese Medicine (Henan Provincial Hospital of Traditional Chinese Medicine), Zhengzhou, Henan 450000, P.R. China.
Chaojie PengDepartment of Cardiovascular Medicine, Guang'anmen Hospital China Academy of Chinese Medical Sciences, Beijing 100053, P.R. China.
Xue MengThe Second Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou, Henan 450000, P.R. China.
Jingnan JiaThe Second Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou, Henan 450000, P.R. China.
Fangfang ZhaoThe Second Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou, Henan 450000, P.R. China.
Yinglin CuiThe Second Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou, Henan 450000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atherosclerosis (AS) is a chronic inflammatory disease characterized by lipid accumulation within the arterial wall. The imbalance between cholesterol influx and efflux, coupled with persistent inflammation, drives the progression of plaque formation. Lipophagy, a selective form of autophagy, specifically targets lipid droplets for lysosomal degradation. Consequently, this process is a notable regulator of cellular lipid homeostasis. In the present review, the core regulatory networks of lipophagy were systematically summarized, including the mechanistic target of rapamycin complex 1/AMP‑activated protein kinase, transcription factor EB (TFEB) and farnesoid X receptor/cAMP response element‑binding protein signaling axes. The multidimensional roles of lipophagy in key cell types involved in AS are also discussed. For example, in macrophages, lipophagy stabilizes plaques by promoting cholesterol efflux and inhibiting foam cell formation; however, dysregulated lipophagy can exacerbate necrotic core formation. In vascular smooth muscle cells, lipophagy regulates phenotype switching and calcification and in endothelial cells, lipophagy mitigates oxidative stress and inflammation. Advances in therapeutic strategies targeting lipophagy were evaluated, ranging from pharmacological agents (such as statins and metformin) to natural compounds (such as berberine and geniposide) and Traditional Chinese Medicine formulas. In conclusion, targeting lipophagy represents a pivotal therapeutic frontier for stabilizing atherosclerotic plaques; however, the broad application of autophagy inducers lacks precision. Future strategies should transition from generalized modulation to cell‑type specific interventions that precisely calibrate the sirtuin 1‑TFEB‑lipophagy axis. Furthermore, elucidating the 'double‑edged' role of lipophagy in late‑stage plaque outcomes is required for developing safe, clinically translatable modulators.

Indexed as

AtherosclerosisAutophagyLipid MetabolismAnimalsHumansMacrophagesSignal Transductionatherosclerosislipid dropletslipophagymacrophagesnatural compoundstherapeutic targets

Identifiers

PMID42169660
PMCPMC13237521

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.